Infliximab (anti-TNF-alpha)

製品コードA2019 別名: Remicade, Remsima, Inflectra

For research use only.
Not for use in humans.

Infliximab (anti-TNF-alpha) (Remicade, Remsima, Inflectra) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

Infliximab (anti-TNF-alpha)
サイズ 価格(税別)
5mg JPY 158800

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(1)

質量管理及び製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Infliximab (anti-TNF-alpha) (Remicade, Remsima, Inflectra) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.
体外試験

Infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.[1] Infliximab does not exacerbate production of inflammatory cytokines, and does not affect expression of TNFR, proliferation of ARPE-19, HTLV-1 proviral load, or apoptosis of ARPE-19. Infliximab does not exacerbate HTLV-1-related inflammation in the eye and represents an acceptable treatment option under HTLV-1 infectious conditions.[3]

体内試験

A single injection of infliximab in diabetic TNF-α(+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 wk. Moreover, the increased TNF-α mRNA expression in diabetic DRG is also attenuated by infliximab, suggesting infliximab's effects may involve the local suppression of TNF-α. Infliximab, an agent currently in clinical use, is effective in targeting TNF-α action and expression and amelioration of diabetic neuropathy in mice.[2] Mice given increasing doses of infliximab produces increasing levels of ADAs. Blood samples from mice given injections of human TNF and infliximab contains infliximab-TNF complexes.[4]

お薦めの試験操作(参考用のみ)

細胞試験:
  • Objective: Glucose uptake assay
    Cells: murine 3T3L1 cell line
    Concentrations: 10 ng/ml
    Incubation Time: 2 hr
    Method: For glucose uptake assay, 3T3L1 mature adipocytes are in vitro cultured for 2 hr at 37°C in humidified 5% CO2 atmosphere, using 6-well cell-culture plates at a density of 30×104 cells per well. Adipocytes are stimulated twice at zero and 60 minutes with 2 μM insulin. In the infliximab-treated group, adipocytes are stimulated with 10 ng/ml infliximab at the beginning of the 2-hr in vitro assay.
    Reference: https://pubmed.ncbi.nlm.nih.gov/30260514

    Objective: Cell Counts
    Cells: ARPE-19 cells, MT-2 cells, Jurkat cells
    Concentrations: 10 μg/ml
    Incubation Time: 24 h, 48 h, 72 h
    Method: ARPE-19 cells (2 × 104) are co-cultured with three times the number of MT2 or Jurkat cells with or without Infliximab. After 0, 24, 48, or 72 h of co-culture, we remove the supernatants, trypsinized ARPE-19, and count the number of ARPE-19 cells under light microscopy.
    Reference: https://pubmed.ncbi.nlm.nih.gov/31620105

    Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

動物試験:
  • Objective: To evaluate the effect on diabetic neuropathy
    Animal Models: 8-week-old C57BL/6J (WT, TNF-α+/+) and TNF-α-deficient (TNFα−/−) mice of strain B6.129S6-Tnftm1Gkl/J in the C57BL/6 background
    Formulation: Saline
    Dosages: 10 μg/g
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/21810933

    Objective: pharmacokinetic (PK) study
    Animal Models: 6–8 week-old female C57BL/6 mice
    Formulation: --
    Dosages: 0.3075 μg/g, 0.384 μg/g, 0.769 μg/g, 1.538 μg/g, 6.15 μg/g, 30.75 μg/g, 246 μg/g
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/31401142

    Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

製品説明

CAS No. 170277-31-3
Isotype Chimeric IgG1
Source Chimeric (mouse/human)
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Infliximab (anti-TNF-alpha)を買う | Infliximab (anti-TNF-alpha) ic50 | Infliximab (anti-TNF-alpha)供給者 | Infliximab (anti-TNF-alpha)を購入する | Infliximab (anti-TNF-alpha)費用 | Infliximab (anti-TNF-alpha)生産者 | オーダーInfliximab (anti-TNF-alpha) | Infliximab (anti-TNF-alpha)化学構造 | Infliximab (anti-TNF-alpha)分子量 | Infliximab (anti-TNF-alpha)代理店